title: Inhibitory potency of choline esterase inhibitors on acetylcholine release and choline esterase activity in fresh specimens of human and rat neocortex.
abstract: Fresh specimens of human and rat neocortex were used to determine direct and indirect inhibitory potencies of choline esterase inhibitors (ChEIs) on ChE and the release of acetylcholine (ACh), respectively. Km values of ChE in homogenates of rat and human neocortex did not differ significantly, whereas the specific activity of ChE was > times higher in the rat. Butyryl ChE exhibited a higher Km and a lower specific activity than ACh esterase in human neocortex. Inhibition of ChE in rat and human tissue was similar [IC50 (nM; human): donepezil: 14, physostigmine: 22, tacrine: 95, galanthamine: 575, rivastigmine: 9120]. In neocortex slices preincubated with [3H]choline, the electrically evoked release of [3H]ACh was inhibited up to 60% by ChEIs (IC50 (nM, rat): donepezil: 30, physostigmine: 39, tacrine: 302, galanthamine: 646, rivastigmine: >10000). Similar IC50-values were also estimated for ACh release in human neocortex, although the maximal inhibitory effects were much smaller ( approximately 20%). We conclude that in comparison to rats: 1) neocortical ChE concentrations are lower and 2) that ChEIs have weaker indirect (muscarine receptor-mediated) presynaptic inhibitory effects in the human brain. We further suggest that a combination of ChEIs with brain-selective muscarine autoreceptor antagonists might help to improve their clinical efficacy.
authors.affiliation: Institute of Experimental and Clinical Pharmacology and Toxicology, Laboratory of Neuropharmacology, University of Freiburg, Freiburg, Germany. rolf.jackisch@pharmakol.uni-freiburg.de
authors.forename: Rolf
authors.initials: R
authors.lastname: Jackisch
authors.forename: Stefan
authors.initials: S
authors.lastname: Förster
authors.forename: Miriam
authors.initials: M
authors.lastname: Kammerer
authors.forename: Anna K
authors.initials: AK
authors.lastname: Rothmaier
authors.forename: Andreas
authors.initials: A
authors.lastname: Ehret
authors.forename: Josef
authors.initials: J
authors.lastname: Zentner
authors.forename: Thomas J
authors.initials: TJ
authors.lastname: Feuerstein
mesh_terms: D000109:Acetylcholine / Q000378:metabolism*; D000293:Adolescent; D000328:Adult; D000368:Aged; D000818:Animals; D002648:Child; D002675:Child, Preschool; D002800:Cholinesterase Inhibitors / Q000494:pharmacology*; D002802:Cholinesterases / Q000378:metabolism*; D000077265:Donepezil; D005702:Galantamine / Q000494:pharmacology; D006801:Humans; D066298:In Vitro Techniques; D007189:Indans / Q000494:pharmacology; D008875:Middle Aged; D019579:Neocortex / Q000187:drug effects* / Q000201:enzymology*; D048448:Phenylcarbamates / Q000494:pharmacology; D010830:Physostigmine / Q000494:pharmacology; D010880:Piperidines / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D000068836:Rivastigmine; D013619:Tacrine / Q000494:pharmacology; D055815:Young Adult
chemical_list: D002800:Cholinesterase Inhibitors; D007189:Indans; D048448:Phenylcarbamates; D010880:Piperidines; D005702:Galantamine; D013619:Tacrine; D000077265:Donepezil; D010830:Physostigmine; D002802:Cholinesterases; D000109:Acetylcholine; D000068836:Rivastigmine